A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Trial Profile

A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Nivolumab (Primary) ; Varlilumab (Primary)
  • Indications Colorectal cancer; Glioblastoma; Head and neck cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celldex Therapeutics
  • Most Recent Events

    • 07 Mar 2018 According to Celldex Therapeutics media release, colorectal cancer (n=21), ovarian cancer (n=58), head and neck squamous cell carcinoma (n=24), renal cell carcinoma (n=14), glioblastoma (n=22) patients has been enrolled data from the study will be presented at appropriate medical meetings in 2018.
    • 12 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Results of phase I portion of this study (n=36) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top